ArticleRheumatology advances in practice2021
Disease severity, flares and treatment patterns in adults with systemic lupus erythematosus in the UK: a real-world observational retrospective cohort analysis.
Article in Rheumatology advances in practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- The SLICC/ACR damage index, assessed using a community-based electronic healthcare record, predicts mortality in SLE patients: results from the United Kingdom Clinical Practice Research Datalink.Rheumatology advances in practice · 2026Article
- Challenges in the diagnosis of systemic lupus erythematosus.Clinical medicine (London, England) · 2025Review
- Prediction of 1-Year Activity in Systemic Lupus Erythematosus: Hierarchical Machine Learning Approach.JMIR formative research · 2025Article
- Temporal trends in glucocorticoids and hydroxychloroquine for treatment of systemic lupus erythematosus in Sweden.Rheumatology (Oxford, England) · 2025Article
- Clinical Outcomes of Patients with SLE Treated with Belimumab, Without Versus With Prior Immunosuppressant Use: a US Claims Database Study.Rheumatology and therapy · 2025Article
- Real-world oral glucocorticoid use in SLE: a nation-wide population-based study using the French medico-administrative (SNDS) claim database.Lupus science & medicine · 2025Article
- Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients.Rheumatology (Oxford, England) · 2025Article
- Trajectories of disease severity and their clinical outcome in real-world patients with systemic lupus erythematosus.Heliyon · 2024Article
- Article
- Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD).Lupus science & medicine · 2024Observational
- Therapeutic changes of systemic lupus erythematosus (SLE) patients in pregnancy and feto-maternal outcomes: a retrospective cohort study.The Journal of international medical research · 2024Article
- Observational
- Burden of disease and real-world treatment patterns of patients with systemic lupus erythematosus in the Australian OPAL dataset.Clinical rheumatology · 2023Article
- Healthcare Resource Use and Costs Associated with Organ Damage in Newly Diagnosed Adults with Systemic Lupus Erythematosus in the UK.Rheumatology and therapy · 2023Article
- Adverse Outcomes, Healthcare Resource Utilization, and Costs Associated with Systemic Corticosteroid use Among Adults with Systemic Lupus Erythematosus in the UK.Rheumatology and therapy · 2023Article
- Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice.RMD open · 2023Article
- Nationwide patterns of hydroxychloroquine dosing and monitoring of retinal toxicity in patients with systemic lupus erythematosus.Scientific reports · 2023Article
- Risk of systemic lupus erythematosus flares according to autoantibody positivity at the time of diagnosis.Scientific reports · 2023Article
- Early intervention in systemic lupus erythematosus: time for action to improve outcomes and health-care utilization.Rheumatology advances in practice · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim was to characterize disease severity, clinical manifestations, treatment patterns and flares in a longitudinal cohort of adults with SLE in the UK.
methodsAdults with SLE were identified in the Clinical Practice Research Datalink-Hospital Episode Statistics database (1 January 2005-31 December 2017). Patients were required to have ≥12 months of data before and after the index date (earliest SLE diagnosis date available). SLE disease severity and flares were classified using adapted claims-based algorithms, which are based on SLE-related conditions, medications and health-service use.
resultsOf 802 patients, 369 had mild, 345 moderate and 88 severe SLE at baseline. A total of 692 initiated treatment in the first year after diagnosis. Five hundred and fifty-seven received antimalarials, 203 immunosuppressants and 416 oral CSs. Information on biologic use in hospitals was unavailable. The mean (S.d.) time to initiating any medication was 177 (385.3) days. The median time to first flare was 63 days (95% CI: 57, 71). At least one flare was experienced by 750 of 802 patients during follow-up; the first flare was mild for 549 of 750, moderate for 116 of 750 and severe for 85 of 750. The mean (S.d.) annual overall flare rate (year 1) was 3.5 (2.5). A shorter median time to first flare was significantly associated with moderate/severe disease (
conclusionOur findings suggest some delay in the initiation of SLE treatment. Most patients experience a flare within 2 months of diagnosis. Early treatment might delay or reduce the severity of the first SLE flare and might translate to slower disease progression, lower accrual of organ damage and better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.